High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share
As Roche’s Vabysmo Mounts Threat
Executive Summary
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.
You may also be interested in...
Regeneron Gets Encouraging Early Data For Bispecifics In Solid Tumors
The company presented positive early data at ESMO for two bispecific antibodies that are important to the company's long-term business strategy, MUC16xCD3 and METxMET.
Faricimab & Asciminib Are First Products To Be Approved By All Access Consortium Regulators
A therapy for wet age-related macular degeneration and a new drug for leukemia have become the first two products to be approved by all countries involved in the international Access Consortium.
Bayer Backs Eylea's Prospects Despite Lucentis Biosimilars
Competition, both branded and generic, is on the rise but the German group believes that Eylea will continue to outperform given its safety and efficacy profile and the potential of a longer-lasting version of the eye therapy.